Challenge:
A European biopharma company developing synthetic lipids required a critical appraisal of data generated by a University research group using natural lipids in oncology. It wished to understand whether the data was compelling enough to redirect its own therapeutic products into the oncology space. Alacrita was commissioned to perform a critical analysis of data generated by the research group and to provide strategic recommendations into whether oncology was a valid therapeutic area for the company.
Solution:
Our team of oncology experts performed a detailed review of the relevant data which spanned 13 peer-reviewed publications describing the proposed mechanism of action for modulating lipid metabolism and the evidence for its potential as an anti-cancer therapy. Our analysis summarized and critiqued all available preclinical data, and additionally provided an assessment of the predicted upstream and downstream biological consequences of target modulation in vivo.
Research & IP Evaluation
Our strategic guidance can help you extract maximum value from your IP portfolio, or if on the buy-side, support your asset acquisition with IP due diligence.